News
March 31, 2008
Advaxis’ Cancer Platform Featured in New Scientist
Preliminary Trials Suggest Promise in Cancer Vaccine
Listeria Monocytogenes-Based Vaccine Mimics “Trojan Horse”
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis Inc., (OTCBB: ADXS), a developmental biotechnology company, has been highlighted in the March 29th magazine edition of New Scientist.
The article, “Bugs Provoke the Immune System Into Fighting Cancer,” explains the Company’s technology, the advantages of using Listeria Monocytogenes as a platform, and the “Trojan Horse” effect that generates an attack on tumors after the patient’s immune system is infected by the bioengineered bacterium. The article discussed the first study conducted in man where both safety and preliminary efficacy data were generated.
“We are pleased New Scientist took such an interest in our approach,” commented Thomas Moore, chairman and CEO of Advaxis. “The full results of this trial will be presented at the American Association for Cancer Research next month. We plan to be moving Lovaxin C into larger, later stage trials later this year.”
For an electronic copy of the article, please visit New Scientist magazine’s website: http://www.newscientist.com/channel/health/mg19726494.900-bugs-provoke -the-immune-system-into-fighting-cancer.html
(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)
About Advaxis, Inc.
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (“Lm”) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system’s cancer-fighting abilities through its proprietary Lm based system, which utilizes multiple simultaneous immunological mechanisms to fight cancer safely.
Advaxis’ lead Lm vaccine candidate – Lovaxin C – targets cervical and head and neck cancers. Current Lm vaccines in development target prostate, breast, ovarian and lung cancers. Advaxis has completed a Phase I/II clinical trial. The Lm platform will also have applications in the fields of infectious disease and autoimmune disorders.
For further information on the Company, please visit: http://www.advaxis.com.
About Lovaxin C Vaccine
Advaxis' Listeria technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Lm, combined with Advaxis” proprietary fusion protein, has the ability to generate a robust immune response and produce an unusually strong and effective multi-level therapeutic immune response to existing cancers and other diseases.
Advaxis’ Lm-based technology is mostly based on Dr. Yvonne Paterson’s decade worth of work in her laboratory at the University of Pennsylvania. The Company’s proprietary antigen fusion protein technology, also suppresses regulatory T cells that inhibit many vaccines in the creation of activated tumor-killing cells.
Lovaxin C was designed to treat women who have already developed cervical cancer as a result of contracting a human papilloma virus (“HPV”) infection, which is the most prevalent sexually transmitted disease in the US. Current prophylactic products on the market are ineffective in treating HPV-infected women.
For further information on Lovaxin C, please visit: http://www.advaxis.com/lc.htm
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Company Contact:
Advaxis, Inc.
Thomas A. Moore
732-545-1590
moore@advaxis.com